Southern Shuanglin Bio-Pharmacy pivots R&D focus, reallocates funds

Southern Shuanglin Bio-Pharmacy's Q3 2025 report highlighted a net profit of yuan 357,181,135.91 for the first nine months, a 34.19% decrease year-over-year. To optimize resource allocation, the company’s board approved a change in the use of raised capital. The "New Product R&D and Supporting Production Line Construction Project" will pivot from "Human Prothrombin Complex" to the "Human Coagulation Factor IX" project due to higher market growth potential and better economic efficiency. The total investment of yuan 34,050.00 will remain unchanged, with yuan 10,000.00 for R&D and yuan 24,050.00 for production line construction.

Additionally, the company will permanently reallocate surplus funds totaling yuan 2,762.43 (including interest and wealth management income) from completed fundraising projects, such as "Replenishment of Working Capital and Debt Repayment" and "Payment of Intermediary Fees," to supplement its working capital for daily operations. This move is pending shareholder approval.

The change in R&D focus is expected to capitalize on the higher market value and growth prospects of Human Coagulation Factor IX, used for treating hemophilia B, a market with fewer current competitors. These strategic shifts aim to enhance the company's competitive edge and improve the efficiency of its capital usage.